Moderna finalizes plan for long-term strategic partnership with Canada
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Subscribe To Our Newsletter & Stay Updated